OncoMatch/Clinical Trials/NCT04986579
Scalp Cooling in MBC
Is NCT04986579 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Paxman Scalp Cooling System and Eribulin for metastatic breast cancer.
Treatment: Paxman Scalp Cooling System · Eribulin · Sacituzumab govitecan · Trastuzumab deruxtecan — This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin. The name of the study intervention involved in this study is: * Paxman Scalp Cooling System
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify